849928-34-3

Usage

Uses

Used in Pharmaceutical Research and Development:
1-CBZ-2-METHYL-PIPERIDIN-4-ONE is used as a precursor in the synthesis of pharmaceutical drugs for its role in creating compounds with potential therapeutic properties. It contributes to the advancement of new drug development by serving as a key component in the formulation of novel medicinal agents.
Used in Organic Synthesis:
In the field of organic synthesis, 1-CBZ-2-METHYL-PIPERIDIN-4-ONE is utilized as a building block for the creation of a variety of chemical compounds. Its structural attributes make it a versatile component in the assembly of complex organic molecules.
Used in Structure-Activity Relationship Studies:
1-CBZ-2-METHYL-PIPERIDIN-4-ONE is employed in the research of structure-activity relationships of bioactive molecules. It aids scientists in understanding how the molecular structure of a compound influences its biological activity, which is crucial for optimizing drug efficacy and safety.

Upstream product

• 75-16-1 methylmagnesium bromide 
• 185847-84-1 benzyl 4-oxo-3,4-dihydropyridine-1(2H)-carboxylate 
• 620-08-6 4-methoxypyridine 
• 501-53-1 benzyl chloroformate 
• 75-24-1 trimethylaluminum 
• 190906-91-3 3,4-dihydro-2-methyl-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester 

Downstream Products

• 921599-74-8 benzyl (2S)-2-methyl-4-oxopiperidine-1-carboxylate 
• 1227685-18-8 benzyl (2S,4S)-4-hydroxy-2-methyl-4-(trichloromethyl)-piperidine-1-carboxylate 
• 1227685-41-7 (2S,4R)-1-benzyl 4-methyl 4-(3-fluorophenylamino)-2-methylpiperidine-1,4-dicarboxylate 
• 1227685-11-1 benzyl (2S,4R)-4-cyano-4-[(3-ethoxy-3-oxopropanoyl)(3-fluorophenyl)amino]-2-methylpiperidine-1-carboxylate 
• 1227685-13-3 benzyl (5R,7S)-1-(3-fluorophenyl)-4-hydroxy-7-methyl-2-oxo-1,8-diazaspiro[4.5]decane-8-carboxylate 
• 1227685-14-4 (5R,7S)-benzyl 1-(3-fluorophenyl)-7-methyl-2-oxo-1,8-diazaspiro[4.5]dec-3-ene-8-carboxylate 
• 1416161-82-4 1-benzyl 4-methyl (2S,4R)-4-[(3-ethoxy-3-oxopropanoyl)(3-fluorophenyl)amino]-2-methylpiperidine-1,4-dicarboxylate 
• 1416161-83-5 8-benzyl 3-ethyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-2,4-dioxo-1,8-diazaspiro[4.5]decane-3,8-dicarboxylate 
• 1416161-72-2 (5R,7S)-1-(3-fluorophenyl)-8-[4-hydroxy-3-(5-methyl-1H-pyrazol-1-yl)benzyl]-7-methyl-1,8-diazaspiro[4.5]dec-3-en-2-one 

Relevant academic research and scientific papers

Highly Enantioselective Catalytic Addition of Grignard Reagents to N-Heterocyclic Acceptors

General methods to prepare chiral N-heterocyclic molecular scaffolds are greatly sought after because of their significance in medicinal chemistry. Described here is the first general catalytic methodology to access a wide variety of chiral 2- and 4-substituted tetrahydro-quinolones, dihydro-4-pyridones, and piperidones with excellent yields and enantioselectivities, utilizing a single catalyst system.

A 1 - tert-butoxy carbonyl -2 - methyl -4 - piperidone method for the synthesis of

The invention discloses a synthesis method of 1-tertbutyloxycarbonyl-2-methyl-4-piperidone. The synthesis method comprises the following steps: step one, synthesis of 1-Cbz-2-methyl-3,4-dihydro-4-piperidone; step two, synthesis of 1-Cbz-2-methyl-4-piperid

Methyl-substitution of an iminohydantoin spiropiperidine β-secretase (BACE-1) inhibitor has a profound effect on its potency

The IC50 of a beta-secretase (BACE-1) lead compound was improved ～200-fold from 11 μM to 55 nM through the addition of a single methyl group. Computational chemistry, small molecule NMR, and protein crystallography capabilities were used to com

ANTIBACTERIAL QUINOLINE DERIVATIVES

The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a pharmaceutically acceptable salt thereof, a N-oxide form thereof or a s

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

LACTAMS AS BETA SECRETASE INHIBITORS

Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermedia

Copper-catalyzed asymmetric 1,4-addition of alkenyl alanes to N-substituted-2-3-dehydro-4-piperidones

Readily available vinyl alanes are used in the Cu-catalyzed asymmetric conjugate addition reaction to N-substituted-2-3-dehydro-4-piperidones. The enhanced reactivity of recently developed and easily prepared phosphine amine ligands in combination with inexpensive Cu(II)naphtenate (CuNp) allows the introduction of a great variety of alkenyl, alkyl, and aryl aluminums in high enantioselectivity.

LACTAMS AS BETA SECRETASE INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment methods of synthesis,

SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as

Discovery of potent and selective inhibitors of 11β-HSD1 for the treatment of metabolic syndrome

High throughput screening efforts have identified a novel class of dichloroaniline amide 11β-HSD1 inhibitors. SAR studies initiated from dichloroaniline 4 focused on retaining the potency and selectivity profile of the lead.